1 minute read
Dec. 10, 2021

BMS-986278: An Oral LPA 1 Antagonist

BMS986278

oral LPA1 GPCR receptor antagonist Ph. II candidate for IPF (60 mg BID) from addressing tox. of prior candidate Journal of Medicinal Chemistry Bristol Myers Squibb, Princeton, NJ

drughunter.com
Drug Hunter Team
Reviewer:  

This month’s cover molecule, BMS-986278 , is an LPA 1 antagonist and oral (up to 125 mg BID) Ph. II clinical candidate for idiopathic pulmonary fibrosis (IPF) (NCT04308681). Reviewer and nominator Christian Kuttruff says: “While there are two approved molecules for the treatment of IPF (pirfenidone from Roche and nintedanib from BI), there is [...]

Loading...

twitterlinkedinemail

Other molecules you may be interested in